Compare Dell Technologies Inc (DELL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Moderna, Inc. — how do they compare? Dell Technologies Inc trades at $462.92 (market cap $284.93B), while Moderna, Inc. trades at $62.4 (market cap $24.18B). The key difference: Dell Technologies Inc is far larger — about 11.8× Moderna, Inc.'s market cap, and Dell Technologies Inc pays a 0.57% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DELL | MRNA | |
|---|---|---|
Market Cap | $284.93B | $24.18B |
Sector | Technology | Health |
52-Week High | $467.27 | $81.80 |
52-Week Low | $111.10 | $22.36 |
Enterprise Value | $304.51B | $20.33B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.
The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
